Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 264

Similar articles for PubMed (Select 15597761)

1.

Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.

Kawakami K, Kawakami M, Kioi M, Husain SR, Puri RK.

J Neurosurg. 2004 Dec;101(6):1004-11.

PMID:
15597761
2.

Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.

Kioi M, Husain SR, Croteau D, Kunwar S, Puri RK.

Technol Cancer Res Treat. 2006 Jun;5(3):239-50. Review.

PMID:
16700620
3.

Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.

Husain SR, Puri RK.

J Neurooncol. 2003 Oct;65(1):37-48. Review.

PMID:
14649884
4.
5.

Interleukin-13 receptor as a unique target for anti-glioblastoma therapy.

Husain SR, Joshi BH, Puri RK.

Int J Cancer. 2001 Apr 15;92(2):168-75.

PMID:
11291041
6.

Cintredekin besudotox in treatment of malignant glioma.

Mut M, Sherman JH, Shaffrey ME, Schiff D.

Expert Opin Biol Ther. 2008 Jun;8(6):805-12. doi: 10.1517/14712598.8.6.805 . Review.

PMID:
18476792
7.
9.

Analysis of biodistribution of intracranially infused radiolabeled interleukin-13 receptor-targeted immunotoxin IL-13PE by SPECT/CT in an orthotopic mouse model of human glioma.

Suzuki A, Leland P, Kobayashi H, Choyke PL, Jagoda EM, Inoue T, Joshi BH, Puri RK.

J Nucl Med. 2014 Aug;55(8):1323-9. doi: 10.2967/jnumed.114.138404. Epub 2014 Jun 19.

10.

Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice.

Li C, Hall WA, Jin N, Todhunter DA, Panoskaltsis-Mortari A, Vallera DA.

Protein Eng. 2002 May;15(5):419-27.

12.

Molecular targeting with recombinant cytotoxins of interleukin-13 receptor alpha2-expressing glioma.

Mintz A, Gibo DM, Madhankumar AB, Debinski W.

J Neurooncol. 2003 Aug-Sep;64(1-2):117-23.

PMID:
12952292
13.

Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme.

Madhankumar AB, Slagle-Webb B, Mintz A, Sheehan JM, Connor JR.

Mol Cancer Ther. 2006 Dec;5(12):3162-9.

14.

Combined effects of radiation and interleukin-13 receptor-targeted cytotoxin on glioblastoma cell lines.

Kawakami K, Kawakami M, Liu Q, Puri RK.

Int J Radiat Oncol Biol Phys. 2005 Sep 1;63(1):230-7.

PMID:
16111594
15.

Efficacy of antiangiogenic targeted toxins against glioblastoma multiforme.

Hall WA, Vallera DA.

Neurosurg Focus. 2006 Apr 15;20(4):E23.

PMID:
16709029
16.

Comparison of intratumoral bolus injection and convection-enhanced delivery of radiolabeled antitenascin monoclonal antibodies.

Sampson JH, Akabani G, Friedman AH, Bigner D, Kunwar S, Berger MS, Bankiewicz KS.

Neurosurg Focus. 2006 Apr 15;20(4):E14.

PMID:
16709019
17.

Analysis of target genes induced by IL-13 cytotoxin in human glioblastoma cells.

Han J, Yang L, Puri RK.

J Neurooncol. 2005 Mar;72(1):35-46.

PMID:
15803373
18.

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA.

J Neurosurg. 2011 Jun;114(6):1662-71. doi: 10.3171/2010.11.JNS101214. Epub 2011 Feb 4.

PMID:
21294620
20.

In vivo evaluation of the boronated porphyrin TABP-1 in U-87 MG intracerebral human glioblastoma xenografts.

Ozawa T, Santos RA, Lamborn KR, Bauer WF, Koo MS, Kahl SB, Deen DF.

Mol Pharm. 2004 Sep-Oct;1(5):368-74.

PMID:
16026007
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk